The latest cancer drugs news
Browsing: Cancer Drug News
Clues to cancer drug’s deadly side effects could make it safer
For some leukaemia patients, the only potential chemotherapy option is a drug that also carries…
Elenagen delays disease progression
CureLab Oncology, a clinical-stage, pre-IPO biotech company, announced that its novel biological agent, Elenagen, has…
‘Protein sandwich’ could transform cancer drug discovery
A breakthrough class of molecular glue identified at the University of Dundee, Scotland, could pave…
FDA approves pembrolizumab with chemoradiotherapy for FIGO 2014 stage III-IVA cervical cancer
On January 12, 2024, the Food and Drug Administration approved pembrolizumab with chemoradiotherapy (CRT) for patients…
European Medicines Agency is looking at approving lazertinib, in combination with amivantamab, for the first-line treatment of patients with EGFR-mutated NSCLC
The Janssen Pharmaceutical Companies of Johnston & Johnson announced the submission of a marketing authorisation application…
FDA grants accelerated approval to pirtobrutinib for chronic lymphocytic leukaemia and small lymphocytic lymphoma
On December 1, 2023, the Food and Drug Administration granted accelerated approval to pirtobrutinib for adults…
Protected: Tecartus® (Brexucabtagene Autoleucel) CAR T-cell therapy now funded in Australia for the treatment of relapsed or refractory mantle cell lymphoma (r/r MCL)
This content is password protected. To view it please enter your password below: Password:
SABCS 2023: Tucatinib plus trastuzumab emtansine may benefit patients with advanced or metastatic HER2-positive breast cancer
A combination of two HER2-targeted drugs, tucatinib (Tukysa) and trastuzumab emtansine (Kadcyla, T-DM1), extended progression-free…
Melanoma and lung cancer drug shows potential in other skin cancer type
Cutaneous squamous cell carcinoma (cSCC), also known as the squamous cell carcinoma of the skin,…
Fast-tracked cancer drug candidate causes substantial levels of mutations and must be investigated for risk of secondary cancer
A cancer drug fast-tracked into clinical trials in the United States could be more damaging…